Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 1;121:57-84.
doi: 10.1016/j.addr.2017.05.017. Epub 2017 Jun 1.

Therapeutic Pro-Fibrogenic Signaling Pathways in Fibroblasts

Affiliations
Free article
Review

Therapeutic Pro-Fibrogenic Signaling Pathways in Fibroblasts

Stefania Cannito et al. Adv Drug Deliv Rev. .
Free article

Abstract

Myofibroblasts (MFs) play a critical role in the progression of chronic inflammatory and fibroproliferative diseases in different tissues/organs, whatever the etiology. Fibrosis is preceded and sustained by persistent injury and inflammatory response in a profibrogenic scenario involving mutual interactions, operated by several mediators and pathways, of MFs and related precursor cells with innate immunity cells and virtually any cell type in a defined tissue. These interactions, mediators and related signaling pathways are critical in initiating and perpetuating the differentiation of precursor cells into MFs that in different tissues share peculiar traits and phenotypic responses, including the ability to proliferate, produce ECM components, migrate and contribute to the modulation of inflammatory response and tissue angiogenesis. Literature studies related to liver, lung and kidney fibrosis have outlined a number of MF-related core regulatory fibrogenic signaling pathways conserved across these different organs and potentially targetable in order to develop effective antifibrotic therapeutic strategies.

Keywords: Antifibrotic therapeutic strategies; Chronic inflammatory diseases; Kidney fibrosis; Liver fibrosis; Lung fibrosis; Myofibroblasts; Profibrogenic pathways.

Similar articles

See all similar articles

Cited by 5 articles

Publication types

Feedback